THE Therapeutic Goods Administration (TGA) has issued a safety advisory around the administration of sodium glucose co-transporter 2 (SGLT2) inhibitors (dapagliflozin and empagliflozin) and increased risk of diabetic ketoacidosis especially perioperatively - medicine information documents are being updated - see tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Jul 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Jul 18
